1
Exhibit 10.4
EXCLUSIVE PATENT LICENSE
AGREEMENT
Effective as of this 4 day of April, 1997 (the "Effective Date"), the University
of Washington, a public institution of higher education having administrative
offices in Seattle, Washington ("UW") and RiboGene, Inc., a company organized
and existing under the laws of California and having a place of business at
00000 Xxxxx Xxxx., Xxxxxxx, Xxxxxxxxxx, 00000 ("Licensee"), agree as follows:
1.0 PREAMBLE
1.1 UW has developed and owns or is in possession of certain technology
("INVENTION," defined further below) relating to regulation of Protein Kinase
Rna (PKR)-activated protein by hepatitis C virus Non-Structural (NS) 5A protein.
1.2 UW desires that the INVENTION be used as soon as possible in the public
interest, and to this end desires to transfer the INVENTION to a company capable
of commercially exploiting the INVENTION.
1.3 Licensee desires, for the purpose of commercial exploitation, to acquire a
license to certain patent rights in and to the INVENTION.
2.0 DEFINITIONS
2.1 Terms defined in this Definitions Article, and parenthetically defined
elsewhere in this Agreement, shall throughout this Agreement have the meaning
here or there provided. Defined terms may be used in the singular or in the
plural, as sense shall require. Terms defined in this Definition Article will be
printed in capital letters for ease of reference.
2.2 "INVENTION" shall mean work done in the University laboratory of Xx. Xxxxxxx
X. Xxxxx identifying a new target for anti-hepatitis C virus therapeutics
consisting of intervention in the regulation of PKR-activated protein by
hepatitis C virus NS5A protein as described in [*].
2.3 "LICENSED PATENTS" shall mean the United States Patent(s) and any Patents
issued from the United States Patent Application(s) listed below, together with
all corresponding foreign patents now issued or issued during the term of this
Agreement, which relate to the INVENTION, and all reissues, divisionals and
continuations thereof:
Patent # Country Issue Date
-------- ------- ----------
[*] [*] [*]
----------------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
2
2.4 "LICENSED SUBJECT MATTER" shall mean any subject matter, including but not
limited to products and processes, covered in whole or in part by any issued,
unexpired patent claim or a claim in a pending patent application contained in
the LICENSED PATENTS in the country in which said subject matter is made, used,
or sold.
2.5 "FIELD OF USE" shall mean all fields of use.
2.6 "SUBFIELD OF USE" shall mean a specific field of use that falls within the
FIELD OF USE, such as, but not limited to, the screening of anti-hepatitis
therapeutics with a certain class of compounds.
2.6 "TERRITORY" shall mean worldwide.
3.0 GRANT
3.1 UW hereby grants to Licensee, and Licensee accepts, an exclusive license,
with the right to sublicense, under the LICENSED PATENTS to import, make, have
made, use, sell, offer for sale and have sold LICENSED SUBJECT MATTER in the
TERRITORY and for the FIELD OF USE of LICENSED PATENTS.
3.2 The license granted above is subject to a reserved non-exclusive license in
UW to make, have made, and use products, processes, or other subject matter
covered by LICENSED PATENTS for research and development purposes.
4.0 SUBLICENSING
4.1 During the term of this Agreement, Licensee shall have the right to grant
non-exclusive sublicenses to LICENSED PATENTS in the LICENSED FIELD OF USE and
for the TERRITORY with terms and conditions not less favorable to UW than those
required of Licensee by Articles 5, 6, 7, 8, 9 and 17 of this Agreement.
4.2 Any and all sublicenses in and to LICENSED PATENTS granted by Licensee shall
be subject prior approval of UW. UW shall not unreasonably withhold or delay
such approval.
4.3 Licensee agrees to forward to UW a copy of any and all fully executed
sublicense agreements pertaining to LICENSED PATENTS within thirty (30) days of
the date of execution of said sublicenses.
5.0 DILIGENCE
page 2 of 15
final Katze/RiboGene
4/3/97
3
5.1 Licensee, during the term of this Agreement, shall utilize reasonable
efforts in proceeding with the development, manufacture, sale, and other
commercial exploitation of LICENSED PATENTS, and in creating a supply and demand
for LICENSED SUBJECT MATTER.
5.2 Licensee shall use reasonable efforts to identify a lead compound as a
therapeutic. Licensee shall use reasonable efforts to meet the following
schedule of performance milestones, counting from the date when a lead compound
is selected for clinical development by mutual agreement between the parties.
Years After Selection of Lead
-----------------------------
Milestone Compound
--------- -----------------------------
[*] [*]
These milestones represent Licensee's realistic estimate of the schedule
it will be able to keep in the event there are no unexpected or clinical
obstacles. Adverse results at any stage could significantly extend the periods
required to meet any or all of the milestones listed.
5.3 In the event that UW becomes aware of third parties that wish to license the
LICENSED PATENTS in a SUBFIELD OF USE UW shall notify Licensee, in writing, of
such third party interest ("Third Part Notification"). Licensee shall have
ninety (90) days from the date of the Third Party Notification to determine if
such third party interest would result in competition to Licensee, and to inform
UW, in writing, with supporting documentation, of Licensee's determination
("Licensee's Determination").
5.3 (i) If Licensee determines that such third party interest would not
result in competition to Licensee, then within sixty (60) days of the date of
Licensee's Determination Licensee shall notify UW, in writing, of which of the
following options it has elected to exercise:
5.3(i)(a) commence active research and development of LICENSED
PATENTS in the field requested by the third party;
5.3(i)(b) grant a sublicense to said third party to import,
make, have made, use, sell, offer for sale and have sold LICENSED SUBJECT MATTER
in the FIELD OF USE; or
page 3 of 15
final Katze/RiboGene
4/3/97
----------------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
4
5.3(i)(c) grant the right to UW to directly license said third
parties to make, have made, use, sell and offer for sale LICENSED SUBJECT MATTER
in tie FIELD OF USE.
In the event Licensee selects the option outlined in Article 5.3(i)(a)
or 5.3(i)(b), Licensee or its sublicensees (if any) shall use reasonable effort
and diligence to proceed with the development, manufacture, and sale or lease of
LICENSED SUBJECT MATTER in the FIELD OF USE.
5.3 (ii) If Licensee determines that such third party interest would
result in competition to Licensee, and UW concurs with this decision, then UW
shall inform the third party that the area of the third party's interest is not
available for licensing.
5.3 (iii) If Licensee determines that such third party interest would
result in competition to Licensee, and UW disputes Licensee's decision, then UW
and Licensee shall resolve this dispute through the following mechanism.
5.3(iii)(a) UW and Licensee shall first attempt to resolve this
dispute through good faith discussions. Any dispute may, at the election of
either party, be referred to the chief executive officers of each party.
5.3(iii)(b) If Licensee and UW are unable to resolve the dispute
of 5.3(iii) through good faith discussions within seventy-five (75) days of
Licensee's Determination, then either party may seek to resolve it by initiating
an Alternative Dispute Resolution ("ADR") in which the Judicial Arbitration and
Mediation Services ("JAMS"), Seattle, Washington shall select the arbitrator
("Arbitrator") as provided herein. If JAMS is not in existence at the time of
such dispute the American Arbitration Association, Seattle, Washington shall be
substituted.
5.3(iii)(c) Selection of Arbitrator. An ADR shall be initiated
by a party by sending written notice thereof to the other party and JAMS, which
notice shall state the issues to be resolved. Within twenty (20) business days
after receipt of such notice, the other party may, by sending written notice to
the initiating party and JAMS, add issues to be resolved. Within twenty (20)
business days after the date of the original ADR notice, JAMS shall nominate to
the parties at least five (5) qualified nominees from JAMS's panel. The parties
shall have ten (10) business days after the receipt of such nominations to agree
on a Arbitrator or, failing to agree, to rank-order their preferences with the
most preferred being given the lowest number, and mail the rank-order to JAMS.
JAMS shall notify the parties of their selection. If all nominees are
unacceptable to a party, the procedure shall be repeated and, if the parties
cannot select an Arbitrator the second time, JAMS shall select the Arbitrator.
5.3(iii)(d) ADR Hearing. The Arbitrator shall hold a hearing to
resolve the issues within one hundred twenty (120) business days after
selection. The location of the hearing shall be Seattle, Washington. Each party
page 4 of 15
final Katze/RiboGene
4/3/97
5
may be represented by counsel. Prior to the hearing, the parties shall be
entitled to engage in discovery under procedures of the Federal Rules of Civil
Procedure; provided, however, that a party may not submit more than thirty (30)
written interrogatories or take more than three (3) depositions. There shall not
be, and the Arbitrator shall not permit, any discovery within thirty (30) days
of the hearing. The Arbitrator shall have sole discretion regarding the
admissibility of evidence and conduct of the hearing. At least ten (10) business
days prior to the hearing, each party shall submit to the other party and the
Arbitrator a copy of all exhibits on which such party intends to rely at the
hearing, a pre-hearing brief (up to 30 pages) and a proposed disposition of the
dispute (up to 5 pages). The proposed disposition shall be limited to proposed
rulings and remedies on each issue, and shall contain no argument on or analysis
of the facts or issues; provided, however, that the parties will not present
proposed monetary remedies. Within ten (10) business days after close of the
hearing, each party may submit a post-hearing brief (up to 5 pages) to the
Arbitrator.
5.3(iii)(e) ADR Ruling; Fees and Expenses. The Arbitrator shall
render a disposition on the proposed rulings as expeditiously as possible after
the hearing, but not later than fifteen (15) business days after the conclusion
of the hearing. The Arbitrator shall rule on each issue and shall adopt in its
entirety the proposed ruling of one of the parties on each issue. The
Arbitrator's disposition shall be final and not appealable, except that either
party shall have the right to appeal such disposition on the basis it was
affected by fraud or bad faith in connection with the ADR proceedings. The
reasonable fees and expenses of the Arbitrator, as well as the standard charges
of JAMS for its assistance, shall be borne equally by the parties or as they may
otherwise agree.
5.3(iii)(f) JAMS Rules. Except as otherwise provided in this
Section 5.3(iii), JAMS Rules shall be used in connection with the ADR.
5.3(iii)(g) Waiver. A party shall not be prohibited from
bringing a claim for resolution under this Section 5 on the ground that the
claim could have been brought during an earlier proceeding under this Section 5.
5.4 If Licensee fails to adhere to the diligence obligations set forth in this
Diligence Article or elsewhere in this Agreement, UW shall notify Licensee, in
writing, and if after written notice thereof such failure is not cured within
sixty (60) days, UW may terminate this Agreement immediately following the end
of the specified sixty (60) day cure period.
6.0 PATENT PROSECUTION AND COST RECOVERY
6.1 Licensee shall conduct the prosecution of any and all patent applications,
whether pending or not yet filed at the time of execution of this Agreement, in
LICENSED PATENTS, and of the maintenance and other management of any and
page 5 of 15
final Katze/RiboGene
4/3/97
6
all issued patents in LICENSED PATENTS; provided that Licensee shall supply to
UW copies of all papers received and filed in connection with the prosecution
thereof in sufficient time for UW to comment hereon. Licensee shall give due
consideration to advice and recommendations of UW.
6.2 In the event of a dispute concerning prosecution of the LICENSED PATENTS, UW
and Licensee shall first attempt to resolve the dispute through good faith
discussions. In the absence of a resolution, either party may refer the dispute
to an independent patent attorney, to which the other party has no reasonable
objection, whose decision the parties agree to adopt. The reasonable fees and
expenses of the independent patent attorney shall be borne by the losing party,
or in the event a compromise position is recommended, equally by the parties.
6.3 Should Licensee elect not to prosecute patent applications and/or maintain
patents in the Licensed Patents in any country, Licensee shall notify UW in
writing of such elections, and UW may, at its sole option and sole expense,
undertake such prosecution. In this case UW shall have no further obligations to
Licensee for, and Licensee shall have no further rights to, the patent
applications and/or patents which Licensee elects not to prosecute and/or
maintain in the countries in which Licensee has elected not to prosecute and/or
maintain such patent applications and/or patents.
7.0 LICENSING FEES AND ROYALTY
7.1 Licensee agrees to pay to UW a one-time, non-refundable, non-creditable
license issue fee of [*] due and payable within thirty (30) days of the
execution of this Agreement. UW shall notify Licensee that such payment is due
by inclusion of an invoice with the execution copies of this Agreement.
7.2 Licensee agrees to pay or cause to be paid to UW a non-refundable,
noncreditable license maintenance fee due and payable within thirty (30) days of
the end of each calendar quarter during the term of this Agreement of [*]. UW
shall invoice RiboGene for such amount. Such license maintenance fee shall be
paid up to and through the date of issuance or date of abandonment of the last
of the PATENT RIGHTS to issue or be abandoned, but not beyond the date of
issuance or abandonment of the last of the PATENT RIGHTS to issue or be
abandoned.
7.3 Licensee agrees to pay or cause to be paid to UW a milestone payment of [*]
upon approval of an NDA on any compound the development of which involved the
use of or could not
page 6 of 15
final Katze/RiboGene
4/3/97
----------------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
7
have been developed but for the PATENT RIGHTS. Such milestone payment shall be
made within thirty (30) days of approval of the NDA.
8.0 PAYMENT AND REPORTS
8.1 Until Licensee or any sublicensees engage in commercial use or sale of
LICENSED SUBJECT MATTER, Licensee shall prepare and submit to UW within thirty
(30) days of December 31 of each year a report regarding the progress of
Licensee and any sublicensees in developing LICENSED SUBJECT MATTER for
commercial exploitation. Said report shall include such particulars as are
necessary to demonstrate compliance with diligence obligations set forth in the
Diligence Article of this Agreement.
8.2 All payments required under this Agreement shall be made in U.S. dollars by
check or money order payable to the University of Washington, and delivered to
UW as specified in this Agreement; or, if so directed in writing by UW, in such
currency, form, and to such account as UW may designate.
8.3 Licensee agrees to pay a late fee for any overdue licensing fee due UW under
terms of this Agreement. The late fee shall be computed as [*] of the
outstanding, unpaid balance. The payment of such a late fee shall not foreclose
or limit UW from exercising any other rights it may have as a consequence of the
lateness of any payment.
9.0 TERM AND TERMINATION OF AGREEMENT
9.1 The term for this Agreement shall extend from the Effective Date of this
Agreement to the last to occur of:
(a) expiration of twenty years (20) years after the Effective Date of
this Agreement;
(b) expiration of the last patent under the LICENSED PATENTS
unless sooner terminated in accordance with the provisions set forth in this
Agreement.
9.2 Article 9.1 notwithstanding, this Agreement shall terminate sixty (60) days
from the date of written notice by UW to Licensee for cause if Licensee fails to
adhere to the diligence obligations or obligations to settle infringements of
LICENSED PATENTS as set forth in the Diligence Article and Infringement Article
of this Agreement. UW's option to terminate this Agreement shall be in addition
to any and all other legal remedies which UW may have for the enforcement of
page 7 of 15
final Katze/RiboGene
4/3/97
----------------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
8
any and all terms hereof, and does not in any way limit any other legal remedy
UW may have.
9.3 Unless the laws then in effect void the effectiveness of this provision,
this Agreement, and the license granted to Licensee hereinabove, shall terminate
immediately in the event that (1) Licensee seeks liquidation, reorganization,
dissolution or winding-up of itself, is insolvent or evidence exists as to its
insolvency, or Licensee makes any general assignment for the benefit of its
creditors; (2) a petition is filed by or against Licensee, or any proceeding is
initiated by or against Licensee, or any proceeding is initiated against
Licensee as a debtor, under any bankruptcy or insolvency law; or (3) a receiver,
trustee, or any similar officer is appointed to take possession, custody, or
control of all or any part of Licensee's assets or property.
9.4 If UW fails to perform an obligation to Licensee as set forth in this
Agreement, Licensee shall notify UW of such failure, in writing, and if after
written notice thereof such failure is not cured within sixty (60) days,
Licensee may terminate this Agreement immediately following the end of the
specified sixty (60) day cure period. Licensee may not terminate this Agreement
for any reason other than with cause.
9.5 The provisions under which this Agreement may be terminated shall be in
addition to any and all other legal remedies which either party may have for the
enforcement of any and all terms hereof, and do not in any way limit any other
legal remedy such party may have.
9.6 Termination of this Agreement shall terminate all rights and licenses
granted to Licensee relating to LICENSED PATENTS.
9.7 Upon termination of this Agreement, any and all existing sublicense
agreement shall be immediately assigned to UW and UW agrees to keep them in
force to the extent that UW is capable of performing as a licensor in place of
Licensee.
9.8 Termination by UW or Licensee under the options set forth in this Agreement
shall not relieve Licensee from any financial obligation to UW accruing prior to
or after termination or from performing according to any and all other
provisions of this Agreement expressly agreed to survive termination.
9.9 In the event that there remain no valid, enforceable, and infringed LICENSED
PATENTS covering LICENSED SUBJECT MATTER, then following termination Licensee
and any sublicensees shall have no further obligation to pay royalties thereon
or to account to UW therefor.
page 8 of 15
final Katze/RiboGene
4/3/97
9
10.0 NOTICES
10.1 Any notice or other communication required or permitted to be given by
either party hereto shall be deemed to have been properly given and be effective
upon the date of delivery if delivered in writing to the respective addresses
set forth below, or to such other address as either party shall designate by
written notice given to the other party. If notice or other communication is
given by facsimile transmission, said notice shall be confirmed by prompt
delivery of the hardcopy original.
In the case of Licensee:
All correspondence regarding this Agreement should be addressed to Xxxxxxx X.
Xxxxxxxxx, C.E.O.
Street Address: 00000 Xxxxx Xxxx.
Xxxxxxx, Xxxxxxxxxx 00000
XXX
Facsimile Address: (000) 000-0000
In the case of UW:
All correspondence regarding this Agreement should be addressed to Director of
the Office of Technology Transfer and copied to Xxxxx X. Xxxxxxx, Manager,
Health Sciences.
Street Address: University of Washington
Office of Technology Transfer
0000 X.X. 00xx Xxxxxx, Xxxxx 000
Xxxxxxx XX 00000-0000
XXX
Facsimile Address: (000) 000-0000
11.0 PROPRIETARY RIGHTS
11.1 Licensee will not, by performance under this Agreement, obtain any
ownership interest in LICENSED PATENTS or any other proprietary rights or
information of UW, its officers, inventors, employees, students, or agents.
page 9 of 15
final Katze/RiboGene
4/3/97
10
12.0 PATENT MARKING
12.1 Licensee shall xxxx, and shall require any sublicensee to xxxx, any and all
material forms of LICENSED SUBJECT MATTER or packaging pertaining thereto made
and sold by Licensee (and/or by its sublicensees) in the United States with an
appropriate patent marking identifying the pendency of any U.S. patent
application and/or any issued U.S. or foreign patent forming any part of
LICENSED PATENTS. All LICENSED SUBJECT MATTER shipped to or sold in other
countries shall be marked in such a manner as to provide constructive notice to
potential infringers pursuant to the patent laws and practice of the country of
manufacture or sale.
13.0 PATENT INFRINGEMENT
13.1 If either party learns of an infringement by a Third Party of the Licensed
Patents in the Field of Use, such party shall promptly notify the other party
and shall provide such other party with available evidence of such infringement.
13.2 Licensee shall have the first right to elect to enforce the Licensed
Patents against third parties worldwide. In the event Licensee shall so elect,
Licensee may do so in UW's name only if required by law, otherwise Licensee
shall institute such suit in Licensee's name only. Licensee shall determine the
worldwide strategy and UW shall assist and cooperate with Licensee in any such
enforcement in the Field of Use. Licensee shall consult with UW and keep UW
regularly advised of Licensee's strategies, plans, progress and results of any
such enforcement action. Licensee shall bear all associated costs and expenses
(including attorney's fees). UW shall, at Licensee's expense, provide reasonable
and prompt cooperation and assistance to Licensee in connection with any such
suit, except that Licensee shall not bear the expense of costs associated with
the use of UW's own resources in providing such cooperation and assistance, such
as employee time. In the event damages or recoveries shall be awarded in such
action, such amounts shall be applied first to reimburse Licensee for any costs,
including attorney's fees, incurred in bringing such action. Remaining amounts
will be divided between UW and Licensee as follows: UW - [*]; Licensee - [*].
13.3 In the event Licensee elects not to enforce the Licensed Patents against
any Third Party in the Field of Use, Licensee shall so notify UW in writing
within one hundred twenty (120) days of the learning of such infringement. Then,
UW shall have the right, but not the obligation, to elect to enforce the
Licensed Patents against such Third Party worldwide in the Field of Use. In the
event UW shall so elect UW shall determine the worldwide strategy and Licensee
shall assist and cooperate with UW in any such enforcement. UW may bring such
suit
page 10 of 15
final Katze/RiboGene
4/3/97
----------------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
11
in its own name, or if required by law, in its and Licensee's name. UW shall
consult with Licensee and keep Licensee regularly advised of UW's strategies
plans, progress and results of any such enforcement action. Licensee shall, at
UW's expense, provide reasonable and prompt cooperation and assistance to
Licensee in connection with any such suit, except that UW shall not bear the
expense of costs associated with the use of Licensee's own resources in such
cooperation and assistance, such as employee time.. UW shall bear all associated
costs and expenses (including attorney's fees). In the event damages or
recoveries shall be awarded in such action, such amounts shall be applied first
to reimburse UW for any costs incurred in bringing such action. Remaining
amounts will be retained by UW.
13.4 Neither Licensee nor UW is obligated under this Agreement to institute a
suit against an alleged infringer of LICENSED PATENTS.
14.0 PATENT VALIDITY
14.1 If Licensee challenges the validity or enforceability of any of LICENSED
PATENTS, Licensee agrees not to suspend any payments and shall put into escrow
any and all payments due UW until such time as that patent in LICENSED PATENTS
is determined to be valid and enforceable by final judgment of a court of
competent jurisdiction from which no appeal can be or is taken. Within thirty
(30) days of such final judgment that the patent in the LICENSED PATENTS is
valid and enforceable all monies in such escrow account shall be paid to UW.
14.2 Except as provided for in Article 14.1, Licensee may, but shall not be
obligated to, elect to defend the Licensed Patents against third party claims
that the Licensed Patents in the Field of Use are invalid or unenforceable.
Licensee shall consult with UW and keep UW regularly advised of Licensee's
strategies, plans, progress and results of any such defense. UW may, at its
expense, select counsel of its choice to assist Licensee's counsel in connection
with such defense and shall assist and cooperate with Licensee in any such
defense. Licensee shall bear all associated costs and expenses (including
attorney's fees) and pay all damages and settlement amounts.
14.3 In the event Licensee does not elect to defend the Licensed Patents as set
forth in 14.1 above, UW may defend the Licensed Patents and shall bear all
associated costs and expenses (including attorney's fees) and pay all damages
and settlement amounts.
14.4 Neither party will take any action including entering into any settlement
action or agree to any settlement that may negatively impact the Licensed
page 11 of 15
final Katze/RiboGene
4/3/97
12
Patents without the express prior written consent of the other party, such
consent not to be unreasonably withheld or delayed.
15.0 USE OF NAMES
15.1 Nothing contained in this Agreement shall be construed as conferring any
right to use in advertising, publicity or other promotional activities any name,
trade name, trademark or other designation of a party hereto including any
contraction, abbreviation or simulation of any of the foregoing, unless the
express written permission of the other party has been obtained. Licensee hereby
expressly agrees not to use the name "University of Washington" without prior
written approval from UW.
16.0 REPRESENTATIONS AND WARRANTIES
16.1 UW represents and warrants that it has the right to grant the license in
and to LICENSED PATENTS.
16.2 Nothing in this Agreement shall be construed as:
(a) A representation or warranty by UW as to the patentability, validity,
scope, or usefulness of LICENSED PATENTS; or
(b) A representation or warranty by UW that anything made, used, sold, or
otherwise disposed of under any license granted in this Agreement is or
will be free from infringement of patents or other proprietary rights not
included in LICENSED PATENTS.
16.3 UW EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED,
PERTAINING TO THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE
INVENTION, LICENSED SUBJECT MATTER, TECHNICAL INFORMATION, OR ANYTHING ELSE
LICENSED, DISCLOSED, OR OTHERWISE PROVIDED TO LICENSEE UNDER THIS AGREEMENT.
UW'S TOTAL LIABILITY UNDER THIS AGREEMENT IS LIMITED TO THE COSTS AND FEES PAID
TO UW UNDER THIS AGREEMENT.
17.0 INDEMNIFICATION
17.1 Licensee agrees to indemnify, hold harmless and defend UW, its officers,
inventors, employees, students, and agents, against any and all claims, suits,
losses, damages, costs, fees and expenses resulting from or arising out of
exercise of this Agreement including, but not limited to, any damages, losses or
liabilities
page 12 of 15
final Katze/RiboGene
4/3/97
13
whatsoever with respect to death or injury to any person and damage to any
property arising from the possession, use, or operation of LICENSED SUBJECT
MATTER by Licensee in any manner whatsoever. This indemnification clause shall
survive the termination of this Agreement.
17.2 From the first human clinical testing of LICENSED SUBJECT MATTER, Licensee
shall maintain general liability insurance, including product liability and
contractual liability coverage, in an amount commensurate with reasonable
commercial practice but in no case less than one million dollars. Licensee's
general liability insurance shall name UW as an additional insured. Licensee
must declare whether the insurance is provided on a "claims-made" form and must
notify UW if coverage is canceled.
17.3 Licensee shall provide to UW within thirty (30) days prior to the
initiation of human clinical trials with respect to LICENSED SUBJECT MATTER
certificates evidencing the existence of the insurance required under Article
17.2. Licensee shall issue irrevocable instructions to its insurance agent and
so the issuing company to notify UW of any discontinuance or lapse of such
insurance not less than thirty (30) days prior to the time that any such
discontinuance or lapse is due to become effective. License shall provide UW a
copy of such instructions upon their transmittal to the insurance agent and
issuing company. Licensee shall further provide UW, at least semi-annually,
proof of continued coverage.
18.0 APPLICABLE LAWS
18.1 Licensee agrees to abide by all applicable federal, state, and local laws
and regulations pertaining to the management and commercial deployment of
LICENSED SUBJECT MATTER under this Agreement.
18.2 LICENSED SUBJECT MATTER may be subject to restrictions concerning the
export of products or technical data from the United States. Accordingly,
Licensee agrees that Licensee shall not export or re-export, directly or
indirectly, any LICENSED SUBJECT MATTER to any country for which the United
States Government or other competent authority at the time of export requires an
export license or other approval, without first obtaining such license or
approval from the appropriate governmental authority.
18.3 This Agreement shall be construed in accordance with, and its performance
shall be governed by, the laws of the State of Washington.
18.4 Any suit, action, or proceeding arising out of or relating to this
Agreement shall be decided in King County, Washington.
page 13 of 15
final Katze/RiboGene
4/3/97
14
19.0 ATTORNEY'S FEES
19.1 If any dispute shall arise under this Agreement, other than a bona fide
dispute concerning the validity and/or scope of LICENSED PATENTS, the prevailing
party shall be entitled to its reasonable attorney's fees and costs of
litigation and appeal.
20.0 GENERAL
20.1 If any provision of this Agreement shall be held to be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining
provisions shall not be in any way affected or impaired thereby.
20.2 No omission or delay of either party hereto in requiring due and punctual
fulfillment of the obligations of any other party hereto shall be deemed to
constitute a waiver by such party of its rights to require such due and punctual
fulfillment, or of any other of its remedies hereunder.
20.3 No amendment or modification hereof shall be valid or binding upon the
parties unless it is made in writing, cites this Agreement, and signed by duly
authorized representatives of UW and Licensee.
20.4 This Agreement, and any rights or obligations hereunder, may be assigned by
the University but shall not be assigned, transferred or delegated in whole or
in part by Licensee, whether by a merger, a sale of assets, or in any other
manner, except with the University's express written approval. Any attempted
assignment, transfer or delegation in breach of this provision shall be deemed
to be void and no effect, and shall entitle the University to terminate this
Agreement upon written notice to Licensee. Except as otherwise provided, this
Agreement shall be binding upon and inure to the benefit of the parties'
successors and lawful assigns.
20.5 The headings of the several sections of this Agreement are inserted for
convenience and reference only, and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement.
20.6 This Agreement embodies the entire understanding of the parties and
supersedes all previous communications, representations, or understandings,
either oral or written, between the parties relating to the subject matter
hereof.
SIGNATURES BEGIN ON NEXT PAGE
page 14 of 15
final Katze/RiboGene
4/3/97
15
IN WITNESS WHEREOF, UW and Licensee have executed this Agreement, in duplicate
originals but collectively evidencing only a single contract, by their
respective duly authorized officers, on the dates hereinafter written.
Licensee University of Washington
By: /s/ XXXXX X. XXXXXX By: /s/ XXXXXX X. XXXXXX, XX.
------------------------------- -------------------------------------
Name: Xxxxx X. Xxxxxx Name: Xxxxxx X. Xxxxxx, Xx., Ph.D.
---------------------------- -----------------------------------
Title: Vice President of Research Title: Director, Technology Transfer
--------------------------- ----------------------------------
Date: April 9, 1997 Date: March 4, 1997
---------------------------- ----------------------------------
UNIVERSITY OF WASHINGTON PERSONNEL:
THE BELOW-NAMED PERSONNEL UNDERSTAND AND CONCUR WITH THIS AGREEMENT.
By: /s/ XXXXXXX X. XXXXX By: /s/ XXXXXXX X. XXXX, XX.
------------------------------- -------------------------------------
Name: Xxxxxxx X. Xxxxx Name: Xxxxxxx X. Xxxx, Xx.
---------------------------- -----------------------------------
Title: Professor, Microbiology Title: Senior Fellow
--------------------------- ----------------------------------
Date: 4/3/97 Date: 4/3/97
---------------------------- ----------------------------------
page 15 of 15
final Katze/RiboGene
4/3/97
